Pipamperon

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of pipamperon
General
Non-proprietary name Pipamperon
other names

1- [4- (4-fluorophenyl) -4-oxobutyl] -1,4-bipiperidine-4-carbamide ( IUPAC ); Floropipamide

Molecular formula C 21 H 30 FN 3 O 2
External identifiers / databases
CAS number
  • 1893-33-0 (pipamperon)
  • 2448-68-2 (pipamperone di hydrochloride )
EC number 606-172-9
ECHA InfoCard 100.119.828
PubChem 4830
ChemSpider 4664
DrugBank DB09286
Wikidata Q415118
Drug information
ATC code

N05 AD05

Drug class

Antipsychotic , sedative

properties
Molar mass 375.48 g · mol -1
Physical state

firmly

Melting point

124.5–126 ° C (pipamperone di hydrochloride )

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances

Dihydrochloride

07 - Warning

Caution

H and P phrases H: 302
P: no P-phrases
Toxicological data

160 mg kg −1 ( LD 50 ,  rat ,  oral )

As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Pipamperon is a psychotropic drug from the group of low-potency neuroleptics (antipsychotics) and belongs to the butyrophenones . It has a clearly sedating and less antipsychotic effect .

pharmacology

Pipamperon mainly blocks serotonin receptors, to a lesser extent D2 and D4 receptors and alpha1 adrenoceptors. Pipamperon has no effect on muscarinic acetylcholine receptors and histamine 1 receptors. The degradation takes place via N -dealkylation and oxidation.

Desired Effects

Pipamperon is used for inner restlessness, sleep disorders , mood swings and the like. have a regulating effect and, for example, promote or stimulate sleep. It can also reduce arousal or aggressiveness .

unwanted effects

Compared to other neuroleptics, Pipamperon is characterized by its relative tolerability; there are no anticholinergic side effects. That is why it is often used in gerontological and child and adolescent psychiatry.

In higher doses, extrapyramidal motor disorders, so-called dyskinesia , can occur. Such movement disorders mainly appear in the orofacial area (around the mouth or face). They can occur as early dyskinesia or late dyskinesia , with pipamperon being a low-potency neuroleptic and late- dyskinesia occurring mainly with highly potent typical neuroleptics .

Neuroleptic malignant syndrome , which can be life-threatening, occurs very rarely .

Gastrointestinal symptoms: loss of appetite , nausea and vomiting.

Endocrine effects: hyperprolactinemia , breast enlargement, menstrual disorders.

Cardiovascular effects: accelerated pulse, low blood pressure, cardiac arrhythmias ( QT time prolongation ) very rarely occur , in one case cardiac arrest occurred.

Other CNS complaints: occasional reports of depression , tiredness and drowsiness, insomnia, headache and seizures have been reported.

Physical withdrawal symptoms: insomnia.

application

Pipamperon is mostly prescribed as a light sleep aid . It is also used as a sedative in the treatment of the elderly and mental illness. It is also given to children with aggressive or autistic behavior. The plasma half-life is 17–22 hours.

Trade names

Monopreparations

Dipiperon (D, CH), Pipamperon HEXAL Saft (D), various generics (D)

See also

Individual evidence

  1. ^ The Merck Index. An Encyclopaedia of Chemicals, Drugs and Biologicals. 14th edition, 2006, p. 1285, ISBN 978-0-911910-00-1 .
  2. ↑ a b Data sheet Pipamperone dihydrochloride from Sigma-Aldrich , accessed on April 21, 2011 ( PDF ).
  3. ↑ Entry on pipamperon in the ChemIDplus database of the United States National Library of Medicine (NLM) .
  4. ↑ Psychotropic drugs for non-psychotic children pharma-kritik Volume 11, Number 21 November 14, 1989
  5. ↑ Compendium of Psychiatric Pharmacotherapy, 8th edition, 2011, p. 306, ISBN 978-3-642-13043-4 .